Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM047DQ)

Drug Name

BCEAB Drug Info

Synonyms

CHEBI:6426; Ac-Leu-Leu-Arg-H; Ac-Leu-Leu-Argininal; Acetyl-L-leucyl-L-leucylargininal; N-Acetyl-L-leucyl-L-leucyl-L-argininal; 55123-66-5; UNII-J97339NR3V; J97339NR3V; 103476-89-7; Acetyl-Leu-Leu-Arg-al; Leupeptin hemisulfate; L-Leucinamide, N-acetyl-L-leucyl-N-(4-((aminoiminomethyl)amino)-1-formylbutyl)-; N-acetyl-L-leucyl-N-[(1S)-4-{[amino(imino)methyl]amino}-1-formylbutyl]-L-leucinamide

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 101210881
TTD Drug ID: DM047DQ

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Chymase (CYM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SUN13834	DMPK34E	Gram-positive bacterial infection	1B74-1G40	Phase 2	[2]
JNJ-10311795	DM7OTQS	Chronic obstructive pulmonary disease	CA22	Phase 2	[3]
ASB17061	DMNVU28	Atopic dermatitis	EA80	Phase 2	[4]
BAY 11-42524	DM8SNEM	Left ventricular dysfunction	BD11	Phase 2	[5]
BAY 1142524	DMHKTGX	Myocardial infarction	BA41-BA43	Phase 2	[6]
2-(N-Morpholino)-Ethanesulfonic Acid	DMZVHSB	Discovery agent	N.A.	Investigative	[7]
Benzylsulfinic Acid	DM7XK28	Discovery agent	N.A.	Investigative	[8]
KM-01221	DMG594K	Cardiovascular disease	BA00-BE2Z	Investigative	[9]
Y-40613	DM412IV	Discovery agent	N.A.	Investigative	[10]
Rac-2q	DMD5TPH	Discovery agent	N.A.	Investigative	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Chymase (CYM)	TT8VUE0	CMA1_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Development of a chymase inhibitor: pharmacological characterization of a chymase inhibitor in inflamed tissue remodeling and fibrosis. Jpn J Pharmacol. 2002 Nov;90(3):206-9.
2	Oral chymase inhibitor SUN13834 ameliorates skin inflammation as well as pruritus in mouse model for atopic dermatitis.Eur J Pharmacol.2008 Dec 28;601(1-3):186-91.
3	Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase. J Med Chem. 2007 Apr 19;50(8):1727-30.
4	Immunology of atopic eczema: overcoming the Th1/Th2 paradigm. Allergy. 2013 Aug;68(8):974-82.
5	ClinicalTrials.gov (NCT02452515) A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY1142524 in Clinically Stable Patients With Left-ventricular Dysfunction.
6	Pharmacokinetics, Safety, and Tolerability of the Novel Chymase Inhibitor BAY 1142524 in Healthy Male Volunteers. Clin Pharmacol Drug Dev. 2019 May;8(4):467-479.
7	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
8	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
9	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2340).
10	Therapeutic potential of a specific chymase inhibitor in atopic dermatitis. Jpn J Pharmacol. 2002 Nov;90(3):214-7.
11	Identification of 6-substituted 4-arylsulfonyl-1,4-diazepane-2,5-diones as a novel scaffold for human chymase inhibitors. Bioorg Med Chem Lett. 2007 Jun 15;17(12):3431-4.